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1. Introduction 
Follicular lymphoma (FL) is an indolent lymphoid neoplasm that is derived from mutated 
germinal center B cells and exhibits a nodular or follicular histologic pattern. It is typically 
composed of a mixture of small, cleaved follicle center cells referred to as centrocytes and 
large noncleaved follicular center cells referred to as centroblasts. FL  accounts for about 20 
% of all lymphomas with the highest incidence in the USA and Western Europe. In Asia and 
in the developing countries the incidence is much lower [1].  
2. The cell of origin of follicular lymphoma 
The current theory that tumors are derived from mutated stem cells called cancer stem cells 
was suggested because stem cells and some cancer cells share self-renewal and 
differentiation capacities [2-4]. Although this hypothesis was postulated in early reports [5-
7],definite proof of their existence came from recent studies in leukemia, where among the 
complete tumor cell population only a small subset of cells could initiate, regenerate and 
maintain the leukemia after transplantation into immunocompromised mice [8,9].Using 
similar functional approaches, a variety of cancer stem cells have been identified in an 
increasing number of epithelial tumors, including breast, prostate, pancreatic and head and 
neck carcinomas [10].Despite these outstanding discoveries in leukemias and solid tumors, 
the existence of lymphoma-originating cells with stem cell properties that may similarly 
generate lymphoma upon mutation remains a controversial and largely unexplored issue 
[11]. Recently, it has been proposed that commited lymphoid progenitors/precursor cells 
with an active V-D-J recombination program are the initiating cells of follicular lymphoma 
when targeted by immunoglobulin-gene translocations in the bone marrow. However, these 
pre-malignant lymphoma initiating cells cannot drive complete malignant transformation, 
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requiring additional cooperating mutations in specific stem cell programs to be converted 
into the lymphoma originating cells able to generate and sustain lymphoma development 
[12]. 
3. Clinical aspects of follicular lymphoma 
Signs and Symptom 
Follicular lymphoma mainly affects older adults. The average age at diagnosis is about 55. 
Men and women are nearly equally affected. Follicular lymphoma is a slow-growing disease 
with minor warning signs that often go unnoticed for a long time  before it is diagnosed.  
The disease is often advanced before a diagnosis is made. Most individuals are diagnosed in 
stage III or IV. However, even in advanced stages there is no immediate threat to life. The 
disease has a "waxing and waning" course, meaning that it flares up and regresses a number 
of times over years. 
The first sign of the condition is often a painless swelling in the neck, armpit or groin that is 
caused by enlarged lymph nodes. However the majority of patients initially present with 
disseminated disease that follows a relatively indolent clinical course. Patients with 
follicular lymphoma typically present with superficial lymph nodes of small to medium 
size. All common superficial territories can be involved by the disease. 
In some patients, the first symptoms are more insidious and related to the slow growth of 
lymph nodes in deep areas, usually in the infradiaphragmatic territories such as the 
retroperitoneum, the mesenteric, or the iliac areas. In those cases, patients may complain of 
atypical symptoms while the tumor bulk can be important, with single or confluent lymph 
nodes. Primary mediastinal involvement is uncommon, as well as isolated splenic 
enlargement[13]. Other symptoms may include loss of appetite and tiredness. The general 
status of the patient is usually preserved, Some people have night sweats, unexplained high 
temperatures and weight loss. These are known as B symptoms. Others have an altered 
performance status. 
Primary involvement of extranodal areas is also very uncommon[14]. The bone marrow is 
involved in 50% to 60% of the cases. Follicular lymphoma can arise in the gastrointestinal 
(GI) tract, predominantly in the duodenum or the small intestine, [15,16]. where it can 
eventually represent the unique site of disease. Lymphoma infiltration may be unifocal or 
multifocal[13]. The new World Health Organization–European Organization for Research on 
Treatment of Cancer (WHO-EORTC) cutaneous lymphoma classification recognizes an 
entity called "primary cutaneous follicle center cell lymphoma" that includes what was 
previously known as "cutaneous follicular lymphoma variant" in the WHO classification. 
[17]. Other follicular lymphomas that may be considered as peculiar entities with a distinct 
behavior are those involving the testis  [18]  and the rare cases of follicular lymphoma 
encountered in children [19]. 
Follicular lymphoma is characterised by response to treatment with disease-free or 
asymptomatic disease intervals, alternating with recurrence/progression and may 
transform to aggressive lymphoma at a rate of around 3% per year [13]. This feature is 
usually—but not systematically—associated with a poor outcome [20].The clinical factors 
associated with the risk of transformation (as well as the biology underlying this 
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phenomenon) are not fully characterized. Some reports indicated that early treatment and 
achievement of a complete response after the first-line therapy were associated with a lower 
risk of transformation in patients with follicular lymphoma [21]. 
4. Clinical prognostic factors  
Several prognostic parameters for follicular lymphomas were identified in the last two 
decades, that led to the development of some prognostic indexes. The International 
Prognostic Index developed for aggressive lymphomas was also found to be able of 
predicting the outcome for patients with follicular lymphoma, but the proportion of patients 
in the higher-risk categories was usually limited. [13] 
The first prognostic system specific to follicular lymphoma was developed by the Italian 
Lymphoma Intergroup (ILI) in the late 1990s [22]. Currently, the Follicular Lymphoma 
International Prognostic Index (FLIPI) [23] is deemed to be more applicable across a range of 
clinical settings . Both systems were developed prior to the introduction of monoclonal 
antibody therapy, which has profoundly changed the treatment and outcome of follicular 
lymphoma [24]. Hence, the FLIPI-2 was recently developed, in a prospective series of 
patients needing treatment, using parameters which were not previously amenable to 
retrospective analysis, and may represent a promising new tool for the identification of 
follicular lymphoma patients with different risk profiles in the era of immunochemotherapy 
[25].  
The description of the Follicular Lymphoma International Prognostic Index (FLIPI) 
represents an important step in identifying patient subgroups with predictable outcome and 
comparing the results of clinical trials. Analyses of gene expression profiles or constitutive 
gene variations may also provide additional insights for prognostication in the near future. 
Furthermore, these data underline the complex interactions between the tumor cells and 
their microenvironment; recent attempts to translate these findings with 
immunohistochemical studies remain unable to robustly predict patient outcome. The 
therapeutic strategies in follicular lymphoma have been transformed by monoclonal 
antibodies, used alone or in combination with chemotherapy. Treatment options should be 
adapted to the clinical features at diagnosis and appear to be able to modify the overall 
survival of some subgroups of patients. Further efforts may focus on strategies that can alter 
the natural history of this disease [13].   
5. Treatment 
There is a general consensus that the natural history of advanced stages of low-grade or 
indolent lymphoma has not changed for the last 30 years. Patients with advanced stages of 
indolent non-Hodgkin's lymphoma have been treated for many years with various 
approaches, including deferred initial therapy (watch and wait), single-agent alkylating 
agents, radiation therapy, combination chemotherapy, and autologous stem-cell 
transplantation. Unfortunately, it has been impossible to demonstrate that the long-term 
prognosis for these patients has significantly changed with any these treatment options [26]. 
The decision to start first-line treatment depends not only on the stage but also on the 
symptoms of the disease [27].According to The Swiss Group for Clinical Cancer Research 
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(SAKK) trials  at least one of the following signs is present in order to start treatment: B 
symptoms; symptomatic enlarged lymph nodes or spleen; steady, clinically significant 
progression of lymphadenopathy, splenomegaly or other follicular lymphoma lesions 
documented by a 50% increase in size over a period of at least 6 months; involvement of at 
least 3 nodal sites (>3 cm), bulky disease (>7 cm), haemoglobin <10g/dL, and platelets <100 
x 109/L due to bone marrow infiltration or splenomegaly [28]. 
Inspite of encouraging early results [29],there is still no solid data to confirm that early 
treatment with rituximab significantly delays the need for new therapy,and  whether this 
approach may alter the natural history of the disease and there is also conflicting results 
Whether early treatment of follicular lymphoma is associated with a decreased risk of 
transformation [27]. 
Horning [30],reported the results of sequential treatment studies conducted at Stanford 
University from 1960 to 1991. Median survival times have ranged from 7 to 10 years, and the 
OS for each group of studies was overlapping. Indolent lymphoma is generally considered 
incurable because no plateau in the survival curve has been demonstrable. However, the 
development of monoclonal antibodies (MoAbs) has revolutionized the treatment of 
patients with follicular lymphoma [26]. 
Many trials utilizing different protocols of combination chemotherapy plus rituximab,eg. 
CVP [31],  CHOP [32,33]   concluded that OS for patients with follicular lymphoma has 
improved over time and that the choice of initial therapy may matter. Sacchi et al 
[34],concluded that  FFS and OS have significantly improved in advanced-stage follicular 
lymphoma patients treated on GISL(  Gruppo Italiano Studio Linfomi) protocols during the 
last 18 years. These improvements are related to evolving front-line and salvage therapies, 
particularly the introduction of rituximab in combination with chemotherapy  
For patients needing therapy, most patients are treated with chemotherapy plus rituximab, 
which has improved response rates, duration of response, and overall survival. Randomized 
studies have shown additional benefit for maintenance rituximab both following 
chemotherapy-rituximab and single agent rituximab [35]. Rituximab maintenance for up to 
2 years has a favorable side effect profile and, based on a systematic meta-analysis, 
substantially prolongs PFS and OS in relapsed disease even after antibody-containing 
induction in patients who have not received antibody as first-line therapy [36]. 
Stem cell transplantation (SCT) including both autologous and allogeneic SCT or 
experimental agent therapy is considered for recurrent disease [35]. 
In the small proportion of patients with limited non-bulky stages I–II, radiotherapy 
(involved or extended field, 30–36 Gy) is the preferred treatment having a curative potential 
[37]. However, In selected cases a watchful waiting may be discussed to avoid the side 
effects of radiation [38]. Radioimmunotherapy or chlorambucil plus rituximab remains an 
alternative in patients with low risk profile or contraindications for a more intensive 
chemoimmunotherapy [39,40]. 
Therfore, the therapeutic strategies in follicular lymphoma have been transformed by 
monoclonal antibodies, used alone or in combination with chemotherapy. Treatment 
options should be adapted to the clinical features at diagnosis and appear to be able to 
modify the overall survival of some subgroups of patients. Further efforts may focus on 
strategies that can alter the natural history of this disease [13]. 
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6. Cytomorphology of follicular lymphoma 
Follicular NHLs are characterized by a follicular growth pattern , but a diffuse area may also 
be present. The follicles of follicular lymphoma were more closely packed together, more 
monotonous in size and shape, and frequently lacked an obvious mantle zone [41].  
These follicles contained a comparatively monomorphic cellular phenotype, mostly of 
centrocytes (small cells with cleaved nuclei) and occasional centroblasts (large cells with 
multilobated nuclei and multiple nucleoli). Mitotic figures were fewer than in reactive 
follicular hyperplasia (RFH) and tingible body macrophages were sparse or absent. 
Polykaryocytes were not observed in RFH or follicular lymphoma and sclerosis was only 
focally present to a minimal degree [42].  
The distinction of FL from RFH is essential, as the latter represents a benign condition [43].A 
number of morphological features are of value in making this distinction; in particular, a 
low density of follicles per unit area, The follicles are separated by wide interfollicular areas 
with prominent mantle zones. The variably sized follicles were composed of a polymorphic 
population of lymphocytes, dendritic cells, and tingible body macrophages that imparted 
a“starry sky” pattern. Mitotic figures were conspicuous. The presence of polarity within 
follicles and the lack of a monomorphic appearance within the follicles all favor RFH [42].  
7. Immunophenotype 
Being  a  mature  B-cell  lymphoma,  FL  express  a  large spectrum  of  B-cell  markers,  such  
as  CD20,  CD19,  CD22,  CD79a, and Pax51 [44].  
FL cells express antigens of the germinal center including CD10 and Bcl-6. Most cases of FL 
express Bcl-2 protein which is highly correlated with the presence of the t(14;18) but may be 
expressed in cases with a clonal karyotype lacking the t(14;18) [45].  
The follicles of RFH and follicular lymphoma stained positively for the B cell marker CD20 
which highlight the difference in the width of the interfollicular region between the follicles. 
In RFH, T cells were predominantly located in the interfollicular zones but also lightly 
percolated throughout the center of the follicles, demonstrated by T cell marker CD3. CD5 
stained T cells are in a nearly identical pattern. T cells stained positively for CD3 and CD5 in 
follicular lymphoma located within the interfollicular zones. The latter also displaying a 
more prominent spillover of CD20-positive cells than in RFH [42].  
Follicles in both RFH and follicular lymphoma were positive for BCL-6. BCL-2 staining 
revealed that the follicular centers in RFH were negative and those in follicular lymphoma 
were positive. CD10 staining was positive for both RFH and follicular lymphoma but 
showed a greater interfollicular staining in follicular lymphoma [41].  
Some cases of both RFH and follicular lymphoma manifested a vague follicular architecture 
that is difficult to detect. In these cases, CD23, a dendritic cell marker, outlined the follicles 
of RFH more clearly by disclosing a scaffolding or a cluster of interconnecting cells with 
elongated cytoplasmic processes. Follicular lymphoma manifested the same pattern of CD23 
staining. Ki-67, a marker for cellular proliferation, showed dense positivity that was 
polarized (unevenly distributed or centered at one edge of the follicle) within RFH follicles. 
In contrast, follicular lymphoma demonstrated a more diffuse, evenly distributed staining 
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pattern within the follicular centers. Polyclonality was evident in RFH, with in situ 
hybridization revealing roughly equal populations of both kappa and lambda light chains. 
In follicular lymphoma rare cells stained positive for kappa or lambda [42].    
 
 
 
Fig. 1. Histopathological and immunohistochemical characterization of reactive lymphoid 
hyperplasia and follicular lymphoma.(Top left) Hematoxylin-eosin staining demonstrates 
follicles in reactive lymphoid hyperplasia (RLH) (inset). The follicles are composed of small 
www.intechopen.com
 Stratification of Patients with Follicular Lymphoma 377 
cells with mitotic figures and tingible body macrophages (arrow). (Top right) Hematoxylin-
eosin-stainedsection of follicular lymphoma shows mostly small centrocytes with cleaved 
nuclei and an occasional centroblast (arrow) with a large nucleus and peripheral nucleoli. 
Inset shows the closer, less well-defined arrangement of several follicles. (Middle left) CD20 
stains B cells within the follicles of RLH. The inset indicates the substantial width of the 
interfollicular zones. (Middle right) CD20 also stains the B cells in the follicles of follicular 
lymphoma; the close arrangement of the follicles can again be appreciated in the 
inset.(Bottom left) CD3 stains T cells in the interfollicular zones (inset); the T cells can also be 
seen percolating throughout the folliclesof RLH. (Bottom right) Follicular lymphoma 
manifests nearly identical CD3 staining, with CD3_ cells prominent in the interfollicular 
zones (inset) as well as scattered within the follicles. (Top left and top right, hematoxylin-
eosin, 400, insets, 25;Middle left through Bottom right, immunoperoxidase reactions, 
diaminobenzidine chromogen, 200, insets 25) [42].   
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Fig. 2. Immunohistochemical characterization of reactive lymphoid hyperplasia and 
follicular lymphoma. (Top left) BCL-6stains B cells within follicles of reactive lymphoid 
hyperplasia (RLH). (Top right) Follicles of follicular lymphoma are also positivefor BCL-6. 
(Middle left) The follicles of RLH are negative for BCL-2. (Middle right) Follicles of follicular 
lymphoma are positivefor BCL-2. (Bottom left) Follicles in RLH are positive for CD10. 
(Bottom right) Follicles (F) of follicular lymphoma are also positive for CD10 but with more 
interfollicular staining than RLH. (Immunoperoxidase reactions, diaminobenzidine 
chromogen,200) [42].   
8. Follicular lymphoma—How many grades?  
The grading of FL was the subject of spirited discussion, both among the authors and the 
participants in the Clinical Advisory Committee. FL has traditionally been graded according 
to the proportion of centroblasts and into three Grades, 1-3 as detailed:  
World Health Organization classification of follicular lymphoma (FL).  
Follicular Lymphoma: Grading & Variants  
Grade 1: 0–5 centroblasts/HPF  
Grade 2: 6–15 centroblasts/HPF  
Grade 3: > 15 centroblasts/HPF  
3a: > 15 centroblasts, but centrocytes are still present  
3b: centroblasts form solid sheets with no residual centrocytes [46].  
Variants:  
Primary cutaneous follicle center lymphoma  
Pediatric follicle center lymphoma  
Intestinal follicle center lymphoma  
Diffuse follicle center lymphoma  
Grade 1, 0–5 centroblasts/HPF  
Grade 2, 6–15centroblasts/HPF[43]  
Pediatric FL lacking an association with the t(14;18). Primary cutaneous follicle center 
lymphoma (PCFCL) may contain a high proportion of large B-cells including large  
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Fig. 3. Further immunohistochemical characterization of reactive lymphoid hyperplasia 
(RLH) and follicular lymphoma. (Topleft) CD20 densely stains this region of RLH without 
obvious follicular architecture. (Top right) CD23 highlights the dendritic cell scaffolding of 
the follicles in an adjacent section. The inset shows a similar dendritic architecture 
broughtout by CD23 in follicular lymphoma. (Bottom left) Ki-67 stains cells within follicles 
of RLH in an uneven distribution; staining is crescentic and more dense at the bottom of the 
follicle. (Bottom right) Follicular cells in follicular lymphoma are more evenly and diffusely 
positive for Ki-67.(Immunoperoxidase reactions, diaminobenzidine chromogen, 200, inset, 
25) [42].   
centrocytes and centroblasts. Evidence of the t(14;18) is uncommon and most cases are BCL2 
negative. Dissemination beyond the skin is rare, and the prognosis is usually excellent [47].  
However, most studies have shown poor interobserver and intraobserver reproducibility. 
Moreover, the clinical significance of the separation of Grades 1 and 2 has been questioned, 
with minimal differences seen in long term outcome. Thus, the 2008 WHO classification 
lumps cases with few centroblasts as “FL Grade 1-2 (low grade)” and does not require or 
recommend further separation. FL Grade 3 is divided into Grades 3A and 3B, based on the 
absence of centrocytes in the latter category. Several studies have identified biological 
differences between these two subtypes, with most cases of FL Grade 3B being more closely 
related to DLBCL at the molecular level [47].  
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However, in clinical practice the separation of Grades 3A and 3B can be challenging. Diffuse 
areas in any Grade 3 FL should be designated as DLBCL (with FL) and are more commonly 
observed in Grade 3B. Further studies are likely to lead to more precise delineation of the 
Grade 3 cases truly belonging within FL and those representing an intrafollicular variant of 
the GCB (germinal center B cell) type of DLBCL.  
The presence of diffuse areas within a FL appears to confer more aggressive clinical 
behavior. In addition, unusual cytological variants can be encountered that are not included 
in the World Health Organization classification, including cases with large centrocytes and 
others with small centroblasts; in some cases the latter may resemble the cytomorphology of 
Burkitt lymphoma and may be associated with MYC oncogene translocations [43].  
A truly diffuse form of FL may be rarely encountered, but on closer inspection, most cases 
demonstrate vaguely follicular architecture that is underappreciated without the routine use 
of immunostains for follicular dendritic cells. When a diagnosis of true diffuse follicle center 
lymphoma is considered, the pathologist is encouraged to demonstrate co-expression of 
CD10 and Bcl-6 as well as presumptive evidence of the t(14;18). Approximately 10% of FL 
cases reveal the presence of a zone of cells resembling marginal zone B cells, immediately 
surrounding neoplastic follicles. Importantly, a residual benign mantle zone is not seen, 
helping to distinguish FL from a marginal zone lymphoma. The area of marginal zone 
differentiation within a FL takes on a distinct morphology with cells having moderate 
amount of pale cytoplasm; moreover, the immunophenotype is also different, with 
downregulation of CD10 and Bcl-6 expression by cells within the marginal zone 
compartment [48].  
Unresolved issues in FL pathology remain and to some extent contribute to problems with 
reproducibility. Diffuse areas in FL are often not identified, due to underutilization of 
follicular dendritic cell stains. Similarly, follicular areas in suspected de novo DLBCL are 
underappreciated. Variability in the cytology of cells within follicles contributes to 
inconsistent reporting of FL grade. Follicular dendritic are commonly misidentified as 
centroblasts, resulting in higher grade and, in general, there is poor interobserver 
reproducibility for the counting of centroblasts. All of these factors lead to inconsistencies in 
the diagnosis and grading of FL biopsies, and to some extent raise questions regarding the 
validity of grading and clinical decision making based on grade [43].  
Finally, a rare form of FL may be seen referred to as “in-situ” FL. In these uncommon cases, 
scattered malignant follicles are identified within lymph nodes revealing mostly benign 
features. The malignant follicles show typically more monomorphic germinal centres (GCs). 
GCs involved in intrafollicular neoplasia/in situ follicular lymphoma are composed mainly 
of centrocytes with no evident atypia. A feature of these centres is the relative absence of 
macrophages with tingible bodies and the absence of polarization into light and dark zones. 
The paucity of large centroblasts reflects their low proliferation rate in insitu FLs. 
Intrafollicular neoplasia/in situ follicular lymphoma is characterized by strong co-
expression of Bcl-2 and CD10 in the involved GCs [49].  
9. Fine needle aspiration cytology  
FNA is a useful tool for staging as well as evaluating recurrences in lymph nodes and extra 
nodal sites without subjecting patients to multiple excisional biopsies. Transformation can 
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occur in some lymph nodes while low-grade lymphoma persists in others. An advantage of 
FNA is the ability to sample multiple lymph nodes, whereas open biopsy of different 
anatomic sites is not feasible  
Grading FL is based on the proportion of centroblasts in neoplastic follicles; therefore, the 
ability to identify the various cellular components in a fine-needle aspirate is the first 
essential step to the grading process. In Papanicolaou stained preparations, centrocytes or 
cleaved follicular center cells are small to medium-sized cells with angulated, elongated, 
twisted, or cleaved nuclei with inconspicuous nucleoli and scant, pale cytoplasm.  
Centroblasts are at least two times larger than a lymphocyte and usually are round or oval 
but occasionally have indented, irregular, or even lobulated nuclei. There is a narrow rim of 
cytoplasm, often basophilic to amphophilic. A large and central nucleolus with chromatin 
clearing around it is characteristic of immunoblasts. In more typical centroblasts, the 
chromatin generally is vesicular with one to three prominent, often peripherally located 
nucleoli. The cells also may be hyperchromatic. Centroblasts tend to be more fragile and, in 
some preparations, may not be preserved well [50].  
It is important not to confuse centroblasts with follicular dendritic reticulum cells, which 
tend to aggregate within the center of the neoplastic follicles. Although dendritic cells have 
nuclei that are similar in size to centroblasts, the nuclei of dendritic cells are somewhat 
coffee bean-shaped with one side typically flattened and with fine, smooth nuclear 
membranes. The cytoplasm is indistinct, not basophilic, in contrast to that of centroblasts. In 
Papanicolaou-stained preparations, the chromatin is pale gray and finely granular with 
small, central, eosinophilic nucleoli. The cytoplasm of dendritic cells form long, dendritic 
processes that can be appreciated in cell blocks by IHC staining for CD21. Large cleaved 
cells also must be distinguished from centroblasts. Although there is an overlap in size with 
centroblasts, large centrocytes are more irregular in shape and lack the prominent nucleoli 
and chromatin pattern of centroblasts [50]  
When it comes to differentiating individual cells, cytologic preparations are superior to 
hematoxylin and eosin-stained histologic sections, although cytologic preparations typically 
are less informative about architecture.  
Cell blocks are complimentary to smears and provide additional architectural clues. The 
FNA process often aspirates intact follicular structures that can be appreciated in the cell 
block. The presence of intact follicles may be proven by special stains on sections of the cell 
block [50].  
10. Grade versus pattern  
All three grades of lymphoma can have varying proportions of follicular and diffuse areas. 
Grade 1 and 2 FL generally have a predominantly follicular pattern. Because they are better 
differentiated, they have retained the ability to recapitulate follicles [ 51].  
Grade 3 FL occurs less frequently than Grade 1 and 2 FL, and a pure follicular pattern in 
Grade 3 FL is even more unusual. In Grade 3 FL, the presence of diffuse areas is more 
common, and most (but not all) studies show that this finding is associated with a worse 
prognosis.  
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In Grade 1 and 2 FL, there is conflicting evidence regarding whether the presence of large, 
diffuse areas or the degree of nodularity may alter prognosis significantly.  
SO the WHO classification system recommends estimating the proportion of follicular and 
diffuse components in the pathology report  
- Follicular (75% follicular),  
- Follicular and diffuse (25–75% follicular),  
- Minimally follicular (25% follicular).  
Note, however, that the proportion of centroblasts within the neoplastic follicles is what 
determines the grade of a FL, not the degree of nodularity. Furthermore, the grade of FL, in 
combination with other clinical factors,ultimately is what influences treatment decisions 
[50].  
11. Cytogenetics of follicular lymphoma  
The t(14;18)(q32;q21) chromosome translocation represents the defining cytogenetic 
hallmark of FL and is encountered in 80%-90% of cases. Its molecular consequence is the 
juxtaposition of the B-cell lymphoma/leukemia 2 (BCL2) proto-oncogene with enhancer 
sequences of the immunoglobulin heavy chain gene (IGH) promoter region, thereby 
deregulating its expression and resulting in an overexpression of the BCL2 protein in the 
neoplastic follicles [52,53]. However, 10–15% of cases do not harbor the t(14;18)(q32;q21) and 
in these t(14;18)-negative cases, other mechanisms are thought to be involved in the 
pathogenesis [54]. Moreover, t(14;18)- positive B cells can be identified in the blood and 
lymphoid tissues of healthy individuals, and the number of t(14;18)-positive cells is 
influenced by gender, personal lifestyle and exposure to toxic substances [55].  
The BCL2 proto oncogene, a potent anti-apoptotic molecule, is expressed in resting B cells in 
the perifollicular mantle zone and in post-follicular B cells, thereby promoting long-lived 
follicular precursor and memory B cells. Germinal center B cells, however, physiologically 
lack BCL2 expression and undergo apoptosis unless they are selected by specific antigens 
that drive them into processes termed somatic hypermutation and class switching. Due to 
the lack of BCL2 expression, amongst other factors, the large bulk of B-cells entering the GC 
microenvironment will be removed by apoptosis. The constitutive overexpression of BCL2 
in germinal center B cells inferred by the t(14;18)(q32;q21) leads to an accumulation of 
inappropriately rescued B cells with a prolonged life span, allowing for the development of 
additional genetic hits to occur, that are required for the establishment of overt FL . Variant 
translocations of the t(14;18), such as the t(2;18) or t(18;22), juxtapose BCL2 to the loci of the 
immunoglobulin light chains (k,l) and, likewise, result in inappropriate and sustained BCL2 
expression in GC B cells [56].  
The occurrence of the t(14;18) in a pre-FL B cell can be viewed as a first hit in a multistep 
process that results in the clonal dysregulation of cell cycle control and apoptosis of the 
tumor cells. During process of lymphomagenesis, a number of additional genetic or 
epigenetic events occur in a non-random fashion that lead to overt FL .For example, 
constitutive expression of activation-induced cytidine deaminase (AID) in the GC 
environment in B cells overexpressing BCL2 may propagate continuous somatic 
hypermutation and class switch recombination activity that results in increased genomic 
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instability. This may, in turn, foster the occurrence of secondary oncogenic hits and, finally, 
result in the malignant transformation to overt FL [57].  
Cong and co-workers[58],described the phenomenon of what they termed follicular 
lymphoma in situ in otherwise reactive, hyperplastic lymph nodes possibly representing the 
morphological equivalent of early, pre-invasive FL.  
12. Secondary chromosomal aberrations in follicular lymphoma  
A number of secondary chromosomal alterations have been described in FL including: 
structural and numerical changes. The complexity of the secondary alterations correlates 
with the grade – the higher the grade, the more complex aberrations are usually 
encountered [59].  
It has long been recognized that these alterations occur in a non-random fashion. Partial 
trisomies of chromosomes 1q, 7, 8 and 18q, and deletions in 1p and 6q have been described 
as the most common secondary alterations, and deletions in the long arm of chromosomes 1 
and 6 and in the short arm of chromosome 17 have been associated with a worse prognosis 
[60]. Some of these alterations may occur early in the course of the disease, whereas others 
might represent late genetic events. In addition, some of the alterations are mutually 
exclusive, while alterations of other chromosomal regions frequently appear together 
possibly leading to a coordinated deregulation of genetic pathways [61].  
Some of the secondary chromosomal alterations may cancel the effect of the t(14;18) that 
initially forms a low-grade neoplasia with a follicular growth pattern and subsequently 
enable the transformation to highgrade lymphoma. This process has been associated with 
three distinct secondary genetic alterations in FL that have a profound impact on the 
biological program and the clinical course in FL. These include an additional introduction of 
a t(8;14)/MYC rearrangement in the tumor cells [62], the inactivation of TP53 by mutation 
and deletion and, finally, the inactivation of p16, frequently occurring by biallelic deletion 
[63].  
The occurrence of a secondary MYC rearrangement in FL deserves particular attention, 
because these cases frequently demonstrate a Burkitt-like appearance and may be detectable 
by virtue of this specific morphology in combination with an overexpression of the BCL2 
protein caused by the t(14;18) that is usually not encountered in classical Burkitt’s 
lymphomas. Some studies suggest that the detection of TP53 mutations in primary 
diagnostic specimens of FL without signs of transformation also characterizes a patient 
subgroup with worse prognosis [64].  
13. BCL2-negative follicular lymphoma  
From recent studies t(14;18)-negative FLs belong to the biologic spectrum of FL, but show 
distinct genetic features as well as gene expression and immunohistochemical profiles that 
differ from their t(14;18)-positive counterparts [65]. The t(14;18)-negative FL appears to 
harbor genetic rearrangements of the BCL6 gene in 3q27[66] or trisomy 3 [67] whereas 
others show BCL2 expression on the immunohistochemical level despite the lack of the 
t(14;18)[68]. Moreover, increased expression of IRF4/MUM1, a protein associated with 
plasma cell differentiation has been described in FL without BCL2 rearrangement [69].  
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14. Molecular genetics of follicular lymphoma 
Immunoglobulin heavy and light chains are rearranged in FL with the variable region genes 
showing extensive and ongoing somatic hypermutation [70, 71]. As a result of these 
mutations in the CDR-regions, PCR primer annealing may be hampered and depending on 
the primers used, immunoglobulin-PCR may not yield monoclonal products in a proportion 
of FL cases (10-40%). Multiplex PCR reactions using BIOMED-2 expanded primer sets detect 
closer to 90% of complete IGH (VH-JH) gene rearrangements, and clonality detection ap-
proximates 100% when primers detecting incomplete IGH (DH-JH) and light chain gene 
rearrangements are included [72]. 
For amplification of complete IGH (VH-JH) gene rearrangement, BIOMED-2 developed 
three sets of VH primers corresponding to the three VH FR regions (FR1, FR2, and FR3). 
Each set of primers consisted of six or seven oligonucleotides capable of annealing to their 
corresponding VH segments (VH1–VH7) with no mismatches for most VH segments. These 
VH primer sets were used in conjunction with a single JH consensus primer. The JH primer 
is fluorescently labeled to allow the detection of  PCR products by Gene Scanning [73].  
For incomplete IGH (DH-JH) rearrangements, seven family-specific DH primers were 
designed based on the high degree of homology within each DH family in combination with 
the consensus JH primer. Primers were designed such that crossannealing to other DH 
family segments would be minimal or preferably absent [73]. 
Six family-specific Vk primers were designed by van Dongen et al [73], to recognize the 
various Vk gene segments of the seven Vk families. The family-specific Vk primers were 
designed to be used in combination with either a set of two Jk primers or a Kde primer.A 
single consensus primer recognizing both Vλ1 and Vλ2 gene segments, as well as a Vλ3 
primer, were designed by van Dongen et al [73], in combination to a single consensus 
primer for the Jλ1, Jλ2, and Jλ3 gene segments.  
The t(14;18) and BCL2 gene rearrangements is one of the best characterized recurrent 
cytogenetic abnormalities in peripheral B-cell lymphoproliferative disease[74]  . FL is 
genetically characterized by this translocation which is present in up to 90% of the grade 1-2 
FL cases [75,76] but the proportion depends on the technique used [77, 78, 79]. BCL2 
rearrangements are much less frequent in grade 3B FL [80]. As a consequence of the 
translocation, the BCL2 gene (anti-apoptotic) from 18q21 is placed under the control of the 
strong enhancers of the IGH locus resulting in the deregulation of its normal pattern of 
expression [81,82]. The BCL2/IGH rearrangement is found in the PB of 25-75% of healthy 
donors, and also in reactive nodes, particularly if using sensitive nested or RT-PCR assays 
[83,84,85]. A recent study suggests that rather than being naive B-cells, these BCL2-re-
arranged cells are memory B-cells [86].  
There is no single gold standard detection strategy for the t(14;18), and a combination of 
cytogenetics and southern blotting have been generally used [87,88]. Interphase FISH 
detection strategies offer an applicable alternative that have the potential to pick up more 
translocations [89]. For molecular diagnostic laboratories PCR-based detection strategies 
offer rapid results, are generally applicable, and can be used for residual disease monitoring. 
However, the primers commonly used have not been designed to take into account recent 
information on the molecular anatomy of the breakpoints. As a consequence when 
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compared to gold standard approaches, PCR-based techniques only detect up to 60% of 
translocations, which seriously impairs the diagnostic capability of PCR. However, 
BIOMED-2 primers have been developed using three multiplex tubes for detection of MBR-
JH, 3'MBR- JH, and mcr-JH to maximize the detection of t(14;18) [73]. ). These data are 
supported by previous report  from our molecular hematology laboratory. We found that 
FISH was superior to PCR in the detection of t(14'18) (q32'q21)-IGH-BCL-2 in formalin-fixed, 
paraffin-embedded tissue samples. Moreover,  strong correlations between the FLIPI score 
and each of interphase FISH and  CD10 expression were demonstrated [90].   
Molecular profiling of many types of lymphoma using RQ-PCR and cDNA microarray has 
been used to predict survival by many researchers [91-94]. Genes involved in cell cycle 
control and DNA synthesis and metabolism (e.g. CXCL12, which is involved in signaling 
transduction and NEK2, which is involved in mitotic regulation, and MAPK1) are 
significantly up-regulated in the aggressive phase of FL[3]. MYC, as a known oncogene, and 
MYC-target genes (SFRS7, LDHA, MTHFD1, NME1, MSH2, and CKS2) are upregulated on 
transformation and may be implicated as a direct transforming factor [95-102].On the other 
hand, there is higher density of the T-cell infiltrate in low-grade FL as compared to high-
grade disease and this is reflected by several T cell–related genes (CD3, CD2, CD69). 
However, genes related to T-cell and macrophage activation including several chemokine 
receptors (CCR1, CCL3, CCL5, CCL8, AKAP12, ILF3, GEM) are significantly upregulated on 
transformation, suggesting an important biologic role. Notably, specific antagonists to 
several of the above-mentioned chemokine receptors are available and offer an attractive 
possibility for therapeutic interventions [103].  
15. Proposed algorithm for stratification of follicular lymphoma 
The National Comprehensive Cancer Network( NCCN)  has recently launched an algorithm  
for stratification of follicular lymphoma (Figure 4). 
 
Fig. 4. Proposed algorithm for stratification of follicular lymphoma (NCCN)  
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